The Price of Illicit Drugs: 1981 through the - The White House
The Price of Illicit Drugs: 1981 through the - The White House
The Price of Illicit Drugs: 1981 through the - The White House
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>The</strong> System To Retrieve Information from Drug Evidence (STRIDE) <strong>of</strong> <strong>the</strong> Drug Enforcement<br />
Administration (DEA) provides <strong>the</strong> most comprehensive data source for laboratory analyses <strong>of</strong> drug<br />
purchases. Researchers have used STRIDE and similar data to develop price series for illicit drugs. 8 Given<br />
<strong>the</strong> large variation in prices over time, across places, between distribution levels and from sale to sale, it is<br />
no wonder that those researchers have <strong>of</strong>ten used sophisticated statistical procedures to identify trends in<br />
drug prices.<br />
This report presents an analysis <strong>of</strong> drug prices commissioned by <strong>the</strong> Office <strong>of</strong> National Drug Control<br />
Policy. Based on STRIDE data from <strong>1981</strong> <strong>through</strong> <strong>the</strong> middle <strong>of</strong> 2000, it presents trends in <strong>the</strong> price per<br />
pure gram and <strong>the</strong> purity <strong>of</strong> cocaine, heroin and methamphetamines. It also presents trends in <strong>the</strong> price <strong>of</strong><br />
marijuana that are unadjusted for THC content, because STRIDE does not report marijuana quality. In<br />
each case, <strong>the</strong> trends are reported for several distribution levels, which is a useful way to estimate <strong>the</strong><br />
markup <strong>of</strong> drug prices from <strong>the</strong> wholesale to <strong>the</strong> retail level.<br />
General Comments about <strong>the</strong> Presentation<br />
This report presents findings with a series <strong>of</strong> graphs and tables. Those graphs and tables are based on<br />
statistical modeling that will not interest most readers. A technical presentation <strong>of</strong> that modeling appears in<br />
an appendix. This report provides both a price and purity figure, with corresponding tables, for cocaine,<br />
heroin and methamphetamine. But marijuana just has <strong>the</strong> price figures, with corresponding tables. As<br />
mentioned, marijuana’s THC content – that is, its counterpart to purity – is unknown in <strong>the</strong> data. Thus,<br />
marijuana price estimates are for bulk grams, not pure grams as with <strong>the</strong> o<strong>the</strong>r three drugs.<br />
For each drug, <strong>the</strong> figures show estimated prices at several hypo<strong>the</strong>tical distribution levels. <strong>The</strong>se<br />
hypo<strong>the</strong>tical levels were set by <strong>the</strong> analysis team to enhance <strong>the</strong> reader’s ability to compare prices as drugs<br />
move from wholesale to retail levels. <strong>The</strong>se levels are hypo<strong>the</strong>tical because, in fact, drug markets are fluid<br />
and lack fixed distribution levels. <strong>The</strong> hypo<strong>the</strong>tical distribution levels vary across drugs because each drug<br />
is transacted in different amounts; for example, a single dose <strong>of</strong> cocaine is not necessarily <strong>the</strong> same as a<br />
single dose <strong>of</strong> heroin. For all four drugs, prices for <strong>the</strong> highest (“wholesale”) distribution level certainly<br />
8 Rhodes, W., Hyatt, R. and Scheiman, P. “<strong>The</strong> <strong>Price</strong> <strong>of</strong> Cocaine, Heroin and Marijuana, <strong>1981</strong>-1993,” Journal <strong>of</strong><br />
Drug Issues, 24 no. 3 (1994): 383-401. Caulkins, J. and Padman, R. “Quantity Discounts and Quality Premia for<br />
<strong>Illicit</strong> <strong>Drugs</strong>,” Journal <strong>of</strong> American Statistical Association, 88 no. 423 (1994): 748-57. Rhodes, W., Truitt, L.,<br />
Kling, R and Nelson, A. “<strong>The</strong> Domestic Monitor Program and <strong>the</strong> Heroin Signature Program: Recommendations<br />
for Changes,” Cambridge, MA, Abt Associates Inc., June 30, 1998.<br />
4